At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 target
Drug / intervention
Sangstat +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sibling Donor Cord Blood Banking and Transplantation
National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Jan 11, 2002·Updated Jul 29, 2016
In Brief
A Phase 2 clinical trial evaluating Sangstat, Cyclophosphamide, and 4 other interventions for Hematologic Diseases and 3 related conditions. Completed, enrolled 30 participants across 15 sites in 2 countries.
Detailed Summary
This study will develop a national cord blood bank for siblings of patients with hemoglobinopathies and thalassemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Diseases, Anemia, Sickle Cell, Beta-Thalassemia, Hematopoietic Stem Cell Transplantation
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1999
First PostedJan 2002
Primary CompletionAug 2006
TodayJul 2026
First PostedJan 11, 2002
Enrollment StartJan 1, 1999
Primary CompletionAug 1, 2006
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 24.5 years ago
Interventions
Sangstatdrug
Cyclophosphamidedrug
Busulfandrug
Mycophenolate Mofetildrug
Cyclosporinedrug
Cord Blood Transplantationprocedure